Ann: DEP irinotecan clinical data presented at AACR meeting, page-25

First 25 Last

Share
Profile

Follow
CaptainBarnacles

11,248 Posts.

713

17/10/23

19:54

Post #: 70393327
Share

Originally posted by Esmer ↑

"Remember though the SP Floor will be $0.085 based off cash in bank."

LOL, there is no SP floor.

If a company looks like it will burn through all its cash without ever becoming profitable, it will eventually go belly-up, and the SP might go to zero long before. Holders will race to dump their shares before they become worthless, even if the company still has cash in the bank. Cash at bank is not available to shareholders. It is available for salaries and directors fees and other company expenses. Burn, baby, burn.

The reality is that several large holders are reducing their holdings. Presumably because of a significant possibility that SPL might never become profitable and might never become an attractive t/o target. With so many tens of millions of shares possibly earmarked for dumping, realistically the SP could be pushed down close to zero at any time.

The whole DEP thing looks increasingly like SPL is just a hobby pharma. Decades of of interesting projects, and always lots of negotiations, but never any substantial income. Progress is probably too slow to generate any significant revenue before the cash at bank runs out in a few years. In my opinion, if DEP was going to happen then it would have happened long ago. I will be very happy if SPL proves me wrong about this and gets some cash out of DEP.

I think that Viraleze offers some hope for shareholders. I think that the pending trial results will probably have a substantial impact on the SP, one way or the other. If the results are good, then for financial reasons I think that SPL needs to rearrange its priorities. And I think that the big shareholders need to put pressure on SPL to do this. Otherwise, many holders may regard even excellent results as immaterial and will try to get out on the spike.

Expand

These big fundies are often like sheep and follow fads, and think the other fundies might know something, by having made some helpful inside connection, when they haven't. Just saying the obvious!

SPL Price at posting: 13.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

KAU

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

Superannuation Essentials: Building Wealth for Your Retirement

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

WTC

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

BTH

Bigtincan bounces 9% after $409M merger proposal sets stage for Nasdaq listing

There are more pages in this discussion • 1 more message in this thread...

First 25 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.2¢		Change 0.000(0.00%)		Mkt cap ! $38.39M

Open	High	Low	Value	Volume
9.2¢	9.3¢	9.1¢	$285.5K	3.101M

Buyers (Bids)

No.	Vol.	Price($)
2	548218	9.2¢

Sellers (Offers)

Price($)	Vol.	No.
9.3¢	95900	2

View Market Depth

No.	Vol.	Price($)
2	548218	0.092
2	71451	0.091
7	98853	0.090
2	86179	0.089
2	45464	0.088

Price($)	Vol.	No.
0.093	95900	2
0.094	69440	2
0.095	182403	3
0.096	104177	1
0.098	11506	1

Last trade - 16.10pm 21/10/2024 (20 minute delay)

SPL (ASX) Chart

Ann: DEP irinotecan clinical data presented at AACR meeting, page-25

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

Superannuation Essentials: Building Wealth for Your Retirement

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

Bigtincan bounces 9% after $409M merger proposal sets stage for Nasdaq listing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: DEP irinotecan clinical data presented at AACR meeting, page-25

Top Stories

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

Superannuation Essentials: Building Wealth for Your Retirement

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

Bigtincan bounces 9% after $409M merger proposal sets stage for Nasdaq listing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News